Clinical trial
Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With…
NCT00217373 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00217373 |
|---|---|
| Title | Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) |
| Official title | A Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-Tricom (B7.1/ICAM/LFA3) and Vaccinia-CEA (6D)-Tricom, in Combination With GM-CSF and Interferon-Alfa-2B in Patients With CEA-Expressing Carcinomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Adult Solid Neoplasm |
| Intervention type | Biological |
| Interventions | Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine, Recombinant Interferon Alfa-2b, Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine, Sargramostim |
| Enrollment | 33 |
| Start date | Jun 1, 2005 |
| Primary completion | Jan 1, 2013 |
| Completion | Mar 1, 2015 |
| First posted | Sep 22, 2005 |
| Last update posted | Apr 20, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: